Paul Rennie interviewed on Marcus Today Podcast., page-43

1. It is time PAR got out a new message for prospective institutional investors, with the words patent and long-term partnership sprinkled over "unique unmet need" & targeted to a wealth investor market place -- doctors and pharmacists.
2. The only deal that should be sought is for MPS, except.....
3. A deal for China restricted to China (but not anytime soon ie after (2), anyway)
All of which lead to the need for a sensible CR by year end at the latest which carries through to labelling, which means NOT through Bell Potter --
the much better deal is a free option deep in the money....
Which is what Weebit did.

As for the reason the share price is where it is, the main different reason to most other stocks is the CR overhang.
Think about it as to what boost is in sight that we don't already expect:
We (posters here) do expect DMOAD evidence, so if we get it, there need to be OTHERS waiting on it or for whom it is really news.

So, PR needs to have his new consultants get into overiride on MPS, and start marketing to institutional investors to buy into a prospective CR.